WO2005041859A3 - Conjugates and compositions for cellular delivery. - Google Patents

Conjugates and compositions for cellular delivery. Download PDF

Info

Publication number
WO2005041859A3
WO2005041859A3 PCT/US2004/013456 US2004013456W WO2005041859A3 WO 2005041859 A3 WO2005041859 A3 WO 2005041859A3 US 2004013456 W US2004013456 W US 2004013456W WO 2005041859 A3 WO2005041859 A3 WO 2005041859A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
compositions
nucleosides
nucleic acids
galactosamine
Prior art date
Application number
PCT/US2004/013456
Other languages
French (fr)
Other versions
WO2005041859A2 (en
Inventor
Chandra Vargeese
Peter Haeberli
Weimin Wang
Tongqian Chen
Original Assignee
Sirna Therapeutics Inc
Chandra Vargeese
Peter Haeberli
Weimin Wang
Tongqian Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/427,160 external-priority patent/US7833992B2/en
Priority claimed from US10/780,447 external-priority patent/US7491805B2/en
Application filed by Sirna Therapeutics Inc, Chandra Vargeese, Peter Haeberli, Weimin Wang, Tongqian Chen filed Critical Sirna Therapeutics Inc
Priority to EP04775924.6A priority Critical patent/EP1622572B1/en
Priority to EP04754277A priority patent/EP1675948A2/en
Priority to US10/861,060 priority patent/US20050137155A1/en
Priority to PCT/US2004/017630 priority patent/WO2005045034A2/en
Priority to US10/863,973 priority patent/US20050143333A1/en
Priority to US10/864,044 priority patent/US20050171040A1/en
Priority to US10/869,638 priority patent/US20050119211A1/en
Priority to US10/871,222 priority patent/US20050119212A1/en
Priority to US10/877,889 priority patent/US20050209179A1/en
Priority to EP04756160A priority patent/EP1644498A2/en
Priority to PCT/US2004/020516 priority patent/WO2005003350A2/en
Priority to CA002528963A priority patent/CA2528963A1/en
Priority to US10/562,561 priority patent/US20060247194A1/en
Priority to US10/879,867 priority patent/US20050124566A1/en
Priority to US10/881,118 priority patent/US20050130181A1/en
Priority to US10/881,580 priority patent/US20060142225A1/en
Priority to US10/883,218 priority patent/US20050124567A1/en
Priority to PCT/US2004/022247 priority patent/WO2005007859A2/en
Priority to US10/888,226 priority patent/US20050124568A1/en
Priority to PCT/US2004/022658 priority patent/WO2005007855A2/en
Priority to US10/892,922 priority patent/US20050124569A1/en
Priority to US10/893,010 priority patent/US20050164224A1/en
Priority to US10/894,475 priority patent/US20050070497A1/en
Priority to US10/898,311 priority patent/US20050277608A1/en
Priority to US10/898,660 priority patent/US20050196765A1/en
Priority to US10/897,902 priority patent/US20050176663A1/en
Priority to US10/903,128 priority patent/US20050182006A1/en
Priority to PCT/US2004/025589 priority patent/WO2005014811A2/en
Priority to US10/916,030 priority patent/US20050159379A1/en
Priority to US10/916,095 priority patent/US20050158735A1/en
Priority to US10/915,896 priority patent/US20050159378A1/en
Priority to US10/918,969 priority patent/US20050153914A1/en
Priority to US10/918,896 priority patent/US20050164966A1/en
Priority to US10/918,987 priority patent/US20050203040A1/en
Priority to US10/919,866 priority patent/US20050176664A1/en
Priority to US10/919,584 priority patent/US20050233997A1/en
Priority to US10/919,964 priority patent/US20050176665A1/en
Priority to EP04781674A priority patent/EP1675950A2/en
Priority to JP2006536610A priority patent/JP2007525205A/en
Priority to US10/922,626 priority patent/US20050159380A1/en
Priority to EP04781983A priority patent/EP1675951A2/en
Priority to US10/922,034 priority patent/US20050164967A1/en
Priority to US10/921,554 priority patent/US20060142226A1/en
Priority to US10/923,580 priority patent/US20050159382A1/en
Priority to PCT/US2004/027404 priority patent/WO2005045041A2/en
Priority to JP2006536614A priority patent/JP2007522794A/en
Priority to PCT/US2004/026941 priority patent/WO2005045032A2/en
Priority to CA002543030A priority patent/CA2543030A1/en
Priority to US10/922,544 priority patent/US20050153915A1/en
Priority to US10/923,640 priority patent/US20050136436A1/en
Priority to EP04781588A priority patent/EP1675949A2/en
Priority to JP2006536612A priority patent/JP2007525206A/en
Priority to US10/923,330 priority patent/US20050153916A1/en
Priority to US10/923,522 priority patent/US20050159381A1/en
Priority to US10/923,142 priority patent/US20050182008A1/en
Priority to US10/923,201 priority patent/US20050182009A1/en
Priority to EP04781836A priority patent/EP1694838A2/en
Priority to US10/923,536 priority patent/US20070042983A1/en
Priority to US10/923,476 priority patent/US20050288242A1/en
Priority to CA002542527A priority patent/CA2542527A1/en
Priority to PCT/US2004/027231 priority patent/WO2005045038A2/en
Priority to US10/923,451 priority patent/US20050256068A1/en
Priority to PCT/US2004/027169 priority patent/WO2005045037A2/en
Priority to CA002543013A priority patent/CA2543013A1/en
Priority to JP2006536609A priority patent/JP2007522793A/en
Priority to US10/923,182 priority patent/US20050176666A1/en
Priority to US10/923,181 priority patent/US20050187174A1/en
Priority to US10/923,270 priority patent/US20050233344A1/en
Priority to US10/922,761 priority patent/US20050267058A1/en
Priority to JP2006536611A priority patent/JP2007527709A/en
Priority to US10/923,470 priority patent/US20050227935A1/en
Priority to PCT/US2004/027403 priority patent/WO2005044981A2/en
Priority to US10/922,675 priority patent/US20050182007A1/en
Priority to US10/923,379 priority patent/US20050239731A1/en
Priority to US10/576,690 priority patent/US20070185043A1/en
Priority to CA002543029A priority patent/CA2543029A1/en
Priority to US10/923,475 priority patent/US20050227936A1/en
Priority to EP04816819A priority patent/EP1675953A2/en
Priority to JP2006536613A priority patent/JP2008506351A/en
Priority to EP04781982A priority patent/EP1682661A2/en
Priority to US10/923,354 priority patent/US20050176024A1/en
Priority to US10/922,554 priority patent/US20080188430A1/en
Priority to PCT/US2004/027367 priority patent/WO2005045040A2/en
Priority to US10/923,329 priority patent/US20050164968A1/en
Priority to US10/923,380 priority patent/US20050196767A1/en
Priority to PCT/US2004/027366 priority patent/WO2005045039A2/en
Priority to CA002542835A priority patent/CA2542835A1/en
Priority to PCT/US2004/026930 priority patent/WO2005045035A2/en
Priority to EP04781956A priority patent/EP1682660A2/en
Priority to US10/923,473 priority patent/US20050191618A1/en
Priority to PCT/US2004/027333 priority patent/WO2005040379A2/en
Priority to PCT/US2004/027294 priority patent/WO2005035759A2/en
Priority to US10/922,340 priority patent/US20050170371A1/en
Priority to US10/923,516 priority patent/US20050176025A1/en
Priority to JP2006526440A priority patent/JP2007505606A/en
Priority to EP04816223A priority patent/EP1670915A2/en
Priority to US10/942,560 priority patent/US20050209180A1/en
Priority to PCT/US2004/031012 priority patent/WO2005028650A2/en
Priority to JP2006526437A priority patent/JP2007505605A/en
Priority to EP04784372A priority patent/EP1664299B1/en
Priority to US10/944,611 priority patent/US20050233998A1/en
Priority to AT04784372T priority patent/ATE431411T1/en
Priority to US10/962,898 priority patent/US20050222066A1/en
Priority to US11/001,347 priority patent/US20050261219A1/en
Priority to US11/014,373 priority patent/US20050196781A1/en
Priority to US11/031,668 priority patent/US20060019913A1/en
Priority to US11/035,813 priority patent/US20060025361A1/en
Priority to US11/054,047 priority patent/US20050287128A1/en
Priority to US11/058,582 priority patent/US20050260620A1/en
Priority to US11/063,415 priority patent/US20050277133A1/en
Priority to EP05724244A priority patent/EP1735443A2/en
Priority to PCT/US2005/006661 priority patent/WO2005105995A2/en
Priority to US11/098,303 priority patent/US20050282188A1/en
Priority to GB0507019A priority patent/GB2415961A/en
Publication of WO2005041859A2 publication Critical patent/WO2005041859A2/en
Priority to US11/140,328 priority patent/US20060019917A1/en
Priority to US11/205,646 priority patent/US20080161256A1/en
Priority to US11/217,936 priority patent/US20060148743A1/en
Priority to US11/234,730 priority patent/US20070270579A1/en
Priority to US11/259,603 priority patent/US20060241075A1/en
Priority to US11/265,730 priority patent/US20070179104A1/en
Priority to US11/299,254 priority patent/US20060217331A1/en
Priority to US11/299,391 priority patent/US7517864B2/en
Priority to US11/311,826 priority patent/US20060211642A1/en
Priority to US11/332,655 priority patent/US20060276422A1/en
Priority to US11/369,108 priority patent/US20070160980A1/en
Priority to US11/395,833 priority patent/US20060287267A1/en
Priority to US11/448,115 priority patent/US20060216747A1/en
Priority to US11/450,856 priority patent/US20060270623A1/en
Priority to US11/455,205 priority patent/US20070049543A1/en
Priority to US11/487,788 priority patent/US20070173473A1/en
Priority to US11/488,374 priority patent/US20080249040A1/en
Priority to US11/592,039 priority patent/US20070185049A1/en
Priority to US11/684,465 priority patent/US20070161596A1/en
Publication of WO2005041859A3 publication Critical patent/WO2005041859A3/en
Priority to US11/748,029 priority patent/US20090239931A1/en
Priority to US11/756,240 priority patent/US20090299045A1/en
Priority to US11/851,090 priority patent/US20080249294A1/en
Priority to US14/712,733 priority patent/US9994853B2/en
Priority to US15/090,421 priority patent/US20160272975A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
    • C12Y103/01—Oxidoreductases acting on the CH-CH group of donors (1.3) with NAD+ or NADP+ as acceptor (1.3.1)
    • C12Y103/01022—3-Oxo-5alpha-steroid 4-dehydrogenase (NADP+) (1.3.1.22), i.e. cortisone alpha-reductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y604/00—Ligases forming carbon-carbon bonds (6.4)
    • C12Y604/01—Ligases forming carbon-carbon bonds (6.4.1)
    • C12Y604/01002—Acetyl-CoA carboxylase (6.4.1.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

This invention features conjugates, degradable linkers, compositions, methods of synthesis, and applications thereof, including cholesterol, galactosamine, and N-acetyl galactosamine derived conjugates of biologically active compounds, including antibodies, antivirals, chemotherapeutics, peptides, proteins, hormones, nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymatic nucleic acids, DNAzymes, allozymes, antisense, dsRNA, siNA, siRNA, triplex oligonucleotides, 2,5-A chimeras, decoys and aptamers.
PCT/US2004/013456 2000-02-11 2004-04-30 Conjugates and compositions for cellular delivery. WO2005041859A2 (en)

Priority Applications (138)

Application Number Priority Date Filing Date Title
EP04775924.6A EP1622572B1 (en) 2003-04-30 2004-04-30 Conjugates and compositions for cellular delivery
EP04754277A EP1675948A2 (en) 2003-10-23 2004-06-03 RNA INTERFERENCE MEDIATED TREATMENT OF PARKINSON DISEASE USING SHORT INTERERING NUCLEIC ACID (siNA)
US10/861,060 US20050137155A1 (en) 2001-05-18 2004-06-03 RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
PCT/US2004/017630 WO2005045034A2 (en) 2003-10-23 2004-06-03 RNA INTERFERENCE MEDIATED TREATMENT OF PARKINSON DISEASE USING SHORT INTERERING NUCLEIC ACID (siNA)
US10/863,973 US20050143333A1 (en) 2001-05-18 2004-06-09 RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US10/864,044 US20050171040A1 (en) 2001-05-18 2004-06-09 RNA interference mediated inhibition of cholesteryl ester transfer protein (CEPT) gene expression using short interfering nucleic acid (siNA)
US10/869,638 US20050119211A1 (en) 2001-05-18 2004-06-16 RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
US10/871,222 US20050119212A1 (en) 2001-05-18 2004-06-18 RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
US10/877,889 US20050209179A1 (en) 2000-08-30 2004-06-25 RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
EP04756160A EP1644498A2 (en) 2003-06-27 2004-06-25 RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA)
PCT/US2004/020516 WO2005003350A2 (en) 2003-06-27 2004-06-25 RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER’S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA002528963A CA2528963A1 (en) 2003-06-27 2004-06-25 Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
US10/562,561 US20060247194A1 (en) 2000-08-30 2004-06-25 Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
US10/879,867 US20050124566A1 (en) 2001-05-18 2004-06-28 RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
US10/881,118 US20050130181A1 (en) 2001-05-18 2004-06-30 RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
US10/881,580 US20060142225A1 (en) 2001-05-18 2004-06-30 RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
US10/883,218 US20050124567A1 (en) 2001-05-18 2004-07-01 RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA)
PCT/US2004/022247 WO2005007859A2 (en) 2003-07-11 2004-07-09 RNA INTERFERENCE MEDIATED INHIBITION OF ACETYL-COA CARBOXYLASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US10/888,226 US20050124568A1 (en) 2001-05-18 2004-07-09 RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA)
PCT/US2004/022658 WO2005007855A2 (en) 2003-07-14 2004-07-14 RNA INTERFERENCE MEDIATED INHIBITION OF B7-H1 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US10/892,922 US20050124569A1 (en) 2001-05-18 2004-07-16 RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
US10/893,010 US20050164224A1 (en) 2001-05-18 2004-07-16 RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
US10/894,475 US20050070497A1 (en) 2001-05-18 2004-07-19 RNA interference mediated inhibtion of tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US10/898,311 US20050277608A1 (en) 2001-05-18 2004-07-23 RNA interference mediated inhibtion of vitamin D receptor gene expression using short interfering nucleic acid (siNA)
US10/898,660 US20050196765A1 (en) 2001-05-18 2004-07-23 RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US10/897,902 US20050176663A1 (en) 2001-05-18 2004-07-23 RNA interference mediated inhibition of protein tyrosine phosphatase type IVA (PRL3) gene expression using short interfering nucleic acid (siNA)
US10/903,128 US20050182006A1 (en) 2001-05-18 2004-07-30 RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
PCT/US2004/025589 WO2005014811A2 (en) 2003-08-08 2004-08-06 RNA INTERFERENCE MEDIATED INHIBITION OF XIAP GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US10/916,030 US20050159379A1 (en) 2001-05-18 2004-08-11 RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
US10/916,095 US20050158735A1 (en) 2001-05-18 2004-08-11 RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
US10/915,896 US20050159378A1 (en) 2001-05-18 2004-08-11 RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US10/918,969 US20050153914A1 (en) 2001-05-18 2004-08-16 RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
US10/918,896 US20050164966A1 (en) 2001-05-18 2004-08-16 RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
US10/918,987 US20050203040A1 (en) 2001-05-18 2004-08-16 RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US10/919,866 US20050176664A1 (en) 2001-05-18 2004-08-17 RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
US10/919,584 US20050233997A1 (en) 2001-05-18 2004-08-17 RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US10/919,964 US20050176665A1 (en) 2001-05-18 2004-08-17 RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
EP04781674A EP1675950A2 (en) 2003-10-23 2004-08-18 Rna interference mediated inhibition of hairless (hr) gene expression using short interfering nucleic acid (sina)
JP2006536610A JP2007525205A (en) 2003-10-23 2004-08-18 Suppression of hairless (HR) gene expression mediated by RNA interference using short interfering nucleic acids (siNA)
US10/922,626 US20050159380A1 (en) 2001-05-18 2004-08-19 RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
EP04781983A EP1675951A2 (en) 2003-10-23 2004-08-19 Rna interference mediated inhibition of cholesteryl ester transfer protein (cetp) gene expression using short interfering nucleic acid (sina)
US10/922,034 US20050164967A1 (en) 2001-05-18 2004-08-19 RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US10/921,554 US20060142226A1 (en) 2001-05-18 2004-08-19 RNA interference mediated inhibition of cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA)
US10/923,580 US20050159382A1 (en) 2001-05-18 2004-08-19 RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
PCT/US2004/027404 WO2005045041A2 (en) 2003-10-23 2004-08-19 Rna interference mediated inhibition of cholesteryl ester transfer protein (cetp) gene expression using short interfering nucleic acid (sina)
JP2006536614A JP2007522794A (en) 2003-10-23 2004-08-19 Inhibition of CETP gene expression via RNA interference using short interfering nucleic acids (siNA)
PCT/US2004/026941 WO2005045032A2 (en) 2003-10-20 2004-08-19 RNA INTERFERENCE MEDIATED INHIBITION OF EARLY GROWTH RESPONSE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA002543030A CA2543030A1 (en) 2003-10-23 2004-08-19 Rna interference mediated inhibition of cholesteryl ester transfer protein (cetp) gene expression using short interfering nucleic acid (sina)
US10/922,544 US20050153915A1 (en) 2001-05-18 2004-08-19 RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
US10/923,640 US20050136436A1 (en) 2001-05-18 2004-08-19 RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
EP04781588A EP1675949A2 (en) 2003-10-23 2004-08-20 RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2006536612A JP2007525206A (en) 2003-10-23 2004-08-20 Inhibition of cholinergic muscarinic receptor (CHRM3) gene expression via RNA interference using short interfering nucleic acids (siNA)
US10/923,330 US20050153916A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
US10/923,522 US20050159381A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA)
US10/923,142 US20050182008A1 (en) 2000-02-11 2004-08-20 RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA)
US10/923,201 US20050182009A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)
EP04781836A EP1694838A2 (en) 2003-10-23 2004-08-20 RNA INTERFERENCE MEDIATED INHIBITION OF GPRA AND AAA1 GENE EXPRESSION USING SHORT NUCLEIC ACID (siNA)
US10/923,536 US20070042983A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US10/923,476 US20050288242A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
CA002542527A CA2542527A1 (en) 2003-10-23 2004-08-20 Rna interferance mediated inhibition of cholinergic muscarinic receptor (chrm3) gene expression using short interfering nucleic acid /sina)
PCT/US2004/027231 WO2005045038A2 (en) 2003-10-23 2004-08-20 RNA INTERFERENCE MEDIATED INHIBITION OF GPRA AND AAA1 GENE EXPRESSION USING SHORT NUCLEIC ACID (siNA)
US10/923,451 US20050256068A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
PCT/US2004/027169 WO2005045037A2 (en) 2003-10-23 2004-08-20 RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA002543013A CA2543013A1 (en) 2003-10-23 2004-08-20 Rna interference mediated inhibition of nogo and nogo receptor gene expression using short interfering nucleic acid (sina)
JP2006536609A JP2007522793A (en) 2003-10-23 2004-08-20 Inhibition of NOGO and / or NOGO receptor gene expression via RNA interference using short interfering nucleic acids (siNA)
US10/923,182 US20050176666A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
US10/923,181 US20050187174A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US10/923,270 US20050233344A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
US10/922,761 US20050267058A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
JP2006536611A JP2007527709A (en) 2003-10-23 2004-08-20 Inhibition of GPRA and / or AAA1 gene expression via RNA interference using short interfering nucleic acids (siNA)
US10/923,470 US20050227935A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
PCT/US2004/027403 WO2005044981A2 (en) 2003-10-23 2004-08-20 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US10/922,675 US20050182007A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US10/923,379 US20050239731A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of MAP kinase gene expression using short interfering nucleic acid (siNA)
US10/576,690 US20070185043A1 (en) 2003-10-23 2004-08-20 Rna interference mediated inhibition of nogo and nogo receptor gene expression using short interfering nucleic acid (sina)
CA002543029A CA2543029A1 (en) 2003-10-23 2004-08-20 Rna interference mediated inhibition of gpra and aaa1 gene expression using short nucleic acid (sina)
US10/923,475 US20050227936A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
EP04816819A EP1675953A2 (en) 2003-10-23 2004-08-20 RNA INTERFERENCE MEDIATED INHIBITION OF RAS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2006536613A JP2008506351A (en) 2003-10-23 2004-08-20 Inhibition of gene expression via RNA interference using short interfering nucleic acids (siNA)
EP04781982A EP1682661A2 (en) 2003-10-23 2004-08-20 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US10/923,354 US20050176024A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of epidermal growth factor receptor (EGFR) gene expression using short interfering nucleic acid (siNA)
US10/922,554 US20080188430A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
PCT/US2004/027367 WO2005045040A2 (en) 2003-10-23 2004-08-20 RNA INTERFERANCE MEDIATED INHIBITION OF CHOLINERGIC MUSCARINIC RECEPTOR (CHRM3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID /siNA)
US10/923,329 US20050164968A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
US10/923,380 US20050196767A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
PCT/US2004/027366 WO2005045039A2 (en) 2003-10-23 2004-08-20 RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA002542835A CA2542835A1 (en) 2003-10-23 2004-08-20 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
PCT/US2004/026930 WO2005045035A2 (en) 2003-10-23 2004-08-20 RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP04781956A EP1682660A2 (en) 2003-10-23 2004-08-20 RNA INTERFERANCE MEDIATED INHIBITION OF CHOLINERGIC MUSCARINIC RECEPTOR (CHRM3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US10/923,473 US20050191618A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
PCT/US2004/027333 WO2005040379A2 (en) 2003-10-23 2004-08-20 RNA INTERFERENCE MEDIATED INHIBITION OF RAS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
PCT/US2004/027294 WO2005035759A2 (en) 2003-08-20 2004-08-20 RNA INTERFERENCE MEDIATED INHIBITION OF HYPOXIA INDUCIBLE FACTOR 1 (HIF1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US10/922,340 US20050170371A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
US10/923,516 US20050176025A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
JP2006526440A JP2007505606A (en) 2003-09-16 2004-09-15 RNA interference-mediated suppression of hepatitis C virus (HCV) expression using small interfering nucleic acids (siNA)
EP04816223A EP1670915A2 (en) 2003-09-16 2004-09-15 RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US10/942,560 US20050209180A1 (en) 2001-05-18 2004-09-15 RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
PCT/US2004/031012 WO2005028650A2 (en) 2003-09-16 2004-09-15 RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2006526437A JP2007505605A (en) 2003-09-16 2004-09-16 RNA interference-mediated suppression of vascular endothelial growth factor gene expression and vascular endothelial growth factor gene receptor gene expression mediated by RNA interference using small interfering nucleic acids (siNA)
EP04784372A EP1664299B1 (en) 2003-09-16 2004-09-16 RNA INTERFERENCE MEDIATED INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US10/944,611 US20050233998A1 (en) 2001-05-18 2004-09-16 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
AT04784372T ATE431411T1 (en) 2003-09-16 2004-09-16 RNA INTERFERENCE-MEDIATED INHIBITION OF THE EXPRESSION OF THE VASCULAR ENDOTHELIAL CELL GROWTH FACTOR GENE AND THE VASCULAR ENDOTHELIAL CELL GROWTH FACTOR RECEPTOR GENE USING SHORT INTERFERING NUCLEIC ACIDS (SINA)
US10/962,898 US20050222066A1 (en) 2001-05-18 2004-10-12 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US11/001,347 US20050261219A1 (en) 2001-05-18 2004-12-01 RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US11/014,373 US20050196781A1 (en) 2001-05-18 2004-12-15 RNA interference mediated inhibition of STAT3 gene expression using short interfering nucleic acid (siNA)
US11/031,668 US20060019913A1 (en) 2001-05-18 2005-01-06 RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US11/035,813 US20060025361A1 (en) 2001-05-18 2005-01-14 RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US11/054,047 US20050287128A1 (en) 2001-05-18 2005-02-09 RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
US11/058,582 US20050260620A1 (en) 2001-05-18 2005-02-15 RNA interference mediated inhibition of retinolblastoma (RBI) gene expression using short interfering nucleic acid (siNA)
US11/063,415 US20050277133A1 (en) 2001-05-18 2005-02-22 RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
EP05724244A EP1735443A2 (en) 2004-04-14 2005-03-01 RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA)
PCT/US2005/006661 WO2005105995A2 (en) 2004-04-14 2005-03-01 RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA)
US11/098,303 US20050282188A1 (en) 2001-05-18 2005-04-04 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
GB0507019A GB2415961A (en) 2004-04-14 2005-04-06 RNA interference (RNAi) of huntingtin (htt) gene
US11/140,328 US20060019917A1 (en) 2001-05-18 2005-05-27 RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
US11/205,646 US20080161256A1 (en) 2001-05-18 2005-08-17 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US11/217,936 US20060148743A1 (en) 2001-05-18 2005-09-01 RNA interference mediated inhibition of histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA)
US11/234,730 US20070270579A1 (en) 2001-05-18 2005-09-23 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US11/259,603 US20060241075A1 (en) 2001-05-18 2005-10-26 RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
US11/265,730 US20070179104A1 (en) 2001-05-18 2005-11-02 RNA interference mediated inhibition of winged helix nude (WHN) gene expression using short interfering nucleic acid (siNA)
US11/299,254 US20060217331A1 (en) 2001-05-18 2005-12-08 Chemically modified double stranded nucleic acid molecules that mediate RNA interference
US11/299,391 US7517864B2 (en) 2001-05-18 2005-12-09 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US11/311,826 US20060211642A1 (en) 2001-05-18 2005-12-19 RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
US11/332,655 US20060276422A1 (en) 2001-05-18 2006-01-13 RNA interference mediated inhibition of B7-H1 gene expression using short interfering nucleic acid (siNA)
US11/369,108 US20070160980A1 (en) 2001-05-18 2006-03-06 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US11/395,833 US20060287267A1 (en) 2001-05-18 2006-03-31 RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
US11/448,115 US20060216747A1 (en) 2001-05-18 2006-06-06 RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US11/450,856 US20060270623A1 (en) 2001-05-18 2006-06-09 RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US11/455,205 US20070049543A1 (en) 2001-05-18 2006-06-16 RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
US11/487,788 US20070173473A1 (en) 2001-05-18 2006-07-17 RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
US11/488,374 US20080249040A1 (en) 2001-05-18 2006-07-18 RNA interference mediated inhibition of sterol regulatory element binding protein 1 (SREBP1) gene expression using short interfering nucleic acid (siNA)
US11/592,039 US20070185049A1 (en) 2001-05-18 2006-11-02 RNA interference mediated inhibition of histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA)
US11/684,465 US20070161596A1 (en) 2000-08-30 2007-03-09 RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA)
US11/748,029 US20090239931A1 (en) 2001-05-18 2007-05-14 RNA INTERFERENCE MEDIATED INHIBITION OF PROTEIN TYROSINE PHOSPHATASE-1B (PTP-1B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US11/756,240 US20090299045A1 (en) 2001-05-18 2007-05-31 RNA Interference Mediated Inhibition Of Interleukin and Interleukin Gene Expression Using Short Interfering Nucleic Acid (siNA)
US11/851,090 US20080249294A1 (en) 2001-05-18 2007-09-06 RNA Interference Mediated Inhibition of Gene Expression Using Short Interfering Nucleic Acid (siNA)
US14/712,733 US9994853B2 (en) 2001-05-18 2015-05-14 Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US15/090,421 US20160272975A1 (en) 2001-05-18 2016-04-04 Chemically modified short interfering nucleic acid molecules that mediate rna interference

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/427,160 2003-04-30
US10/427,160 US7833992B2 (en) 2001-05-18 2003-04-30 Conjugates and compositions for cellular delivery
US10/780,447 2004-02-13
US10/780,447 US7491805B2 (en) 2001-05-18 2004-02-13 Conjugates and compositions for cellular delivery

Related Parent Applications (4)

Application Number Title Priority Date Filing Date
US10/427,160 Continuation-In-Part US7833992B2 (en) 2000-02-11 2003-04-30 Conjugates and compositions for cellular delivery
US10/427,160 Continuation US7833992B2 (en) 2000-02-11 2003-04-30 Conjugates and compositions for cellular delivery
US10/780,447 Continuation-In-Part US7491805B2 (en) 2000-02-11 2004-02-13 Conjugates and compositions for cellular delivery
US10/780,447 Continuation US7491805B2 (en) 2000-02-11 2004-02-13 Conjugates and compositions for cellular delivery

Related Child Applications (81)

Application Number Title Priority Date Filing Date
PCT/US2003/005028 Continuation-In-Part WO2003074654A2 (en) 2000-02-11 2003-02-20 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US10/861,060 Continuation-In-Part US20050137155A1 (en) 2001-05-18 2004-06-03 RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
US10/864,044 Continuation-In-Part US20050171040A1 (en) 2001-05-18 2004-06-09 RNA interference mediated inhibition of cholesteryl ester transfer protein (CEPT) gene expression using short interfering nucleic acid (siNA)
US10/863,973 Continuation-In-Part US20050143333A1 (en) 2001-05-18 2004-06-09 RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US10/869,638 Continuation-In-Part US20050119211A1 (en) 2001-05-18 2004-06-16 RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
US10/871,222 Continuation-In-Part US20050119212A1 (en) 2001-05-18 2004-06-18 RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
US10/877,889 Continuation-In-Part US20050209179A1 (en) 2000-08-30 2004-06-25 RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US10/879,867 Continuation-In-Part US20050124566A1 (en) 2001-05-18 2004-06-28 RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
US10/881,118 Continuation-In-Part US20050130181A1 (en) 2001-05-18 2004-06-30 RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
US10/881,580 Continuation-In-Part US20060142225A1 (en) 2001-05-18 2004-06-30 RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
US10/883,218 Continuation-In-Part US20050124567A1 (en) 2001-05-18 2004-07-01 RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA)
US10/888,226 Continuation-In-Part US20050124568A1 (en) 2001-05-18 2004-07-09 RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA)
US10/893,010 Continuation-In-Part US20050164224A1 (en) 2001-05-18 2004-07-16 RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
US10/892,922 Continuation-In-Part US20050124569A1 (en) 2001-05-18 2004-07-16 RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
US10/894,475 Continuation-In-Part US20050070497A1 (en) 2001-05-18 2004-07-19 RNA interference mediated inhibtion of tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US10/898,311 Continuation-In-Part US20050277608A1 (en) 2001-05-18 2004-07-23 RNA interference mediated inhibtion of vitamin D receptor gene expression using short interfering nucleic acid (siNA)
US10/897,902 Continuation-In-Part US20050176663A1 (en) 2001-05-18 2004-07-23 RNA interference mediated inhibition of protein tyrosine phosphatase type IVA (PRL3) gene expression using short interfering nucleic acid (siNA)
US10/898,660 Continuation-In-Part US20050196765A1 (en) 2001-05-18 2004-07-23 RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US10/903,128 Continuation-In-Part US20050182006A1 (en) 2001-05-18 2004-07-30 RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
US10/916,030 Continuation-In-Part US20050159379A1 (en) 2001-05-18 2004-08-11 RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
US10/915,896 Continuation-In-Part US20050159378A1 (en) 2001-05-18 2004-08-11 RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US10/916,095 Continuation-In-Part US20050158735A1 (en) 2001-05-18 2004-08-11 RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
US10/918,987 Continuation-In-Part US20050203040A1 (en) 2001-05-18 2004-08-16 RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US10/918,969 Continuation-In-Part US20050153914A1 (en) 2001-05-18 2004-08-16 RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
US10/918,896 Continuation-In-Part US20050164966A1 (en) 2001-05-18 2004-08-16 RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
US10/919,964 Continuation-In-Part US20050176665A1 (en) 2001-05-18 2004-08-17 RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
US10/919,584 Continuation-In-Part US20050233997A1 (en) 2001-05-18 2004-08-17 RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US10/919,866 Continuation-In-Part US20050176664A1 (en) 2001-05-18 2004-08-17 RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
US10/922,034 Continuation-In-Part US20050164967A1 (en) 2001-05-18 2004-08-19 RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US10/923,580 Continuation-In-Part US20050159382A1 (en) 2001-05-18 2004-08-19 RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US10/923,640 Continuation-In-Part US20050136436A1 (en) 2001-05-18 2004-08-19 RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
US10/922,626 Continuation-In-Part US20050159380A1 (en) 2001-05-18 2004-08-19 RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
US10/922,544 Continuation-In-Part US20050153915A1 (en) 2001-05-18 2004-08-19 RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
US10/921,554 Continuation-In-Part US20060142226A1 (en) 2001-05-18 2004-08-19 RNA interference mediated inhibition of cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA)
US10/923,476 Continuation-In-Part US20050288242A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US10/922,340 Continuation-In-Part US20050170371A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
US10/923,473 Continuation-In-Part US20050191618A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
US10/923,142 Continuation-In-Part US20050182008A1 (en) 2000-02-11 2004-08-20 RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA)
US10/922,761 Continuation-In-Part US20050267058A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
US10/923,470 Continuation-In-Part US20050227935A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
US10/923,451 Continuation-In-Part US20050256068A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
US10/923,329 Continuation-In-Part US20050164968A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
US10/923,536 Continuation-In-Part US20070042983A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US10/923,182 Continuation-In-Part US20050176666A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
US10/923,475 Continuation-In-Part US20050227936A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
US10/923,516 Continuation-In-Part US20050176025A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
US10/923,181 Continuation-In-Part US20050187174A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US10/923,354 Continuation-In-Part US20050176024A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of epidermal growth factor receptor (EGFR) gene expression using short interfering nucleic acid (siNA)
US10/923,115 Continuation-In-Part US20050079610A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
US10/923,201 Continuation-In-Part US20050182009A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)
US10/922,675 Continuation-In-Part US20050182007A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US10/923,380 Continuation-In-Part US20050196767A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
US10/923,522 Continuation-In-Part US20050159381A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA)
US10/923,270 Continuation-In-Part US20050233344A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
US10/923,379 Continuation-In-Part US20050239731A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of MAP kinase gene expression using short interfering nucleic acid (siNA)
US10/923,330 Continuation-In-Part US20050153916A1 (en) 2001-05-18 2004-08-20 RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
US10/942,560 Continuation-In-Part US20050209180A1 (en) 2001-05-18 2004-09-15 RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US10/944,611 Continuation-In-Part US20050233998A1 (en) 2001-05-18 2004-09-16 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US10/962,898 Continuation-In-Part US20050222066A1 (en) 2001-05-18 2004-10-12 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US11/001,347 Continuation-In-Part US20050261219A1 (en) 2001-05-18 2004-12-01 RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US11/014,373 Continuation-In-Part US20050196781A1 (en) 2001-05-18 2004-12-15 RNA interference mediated inhibition of STAT3 gene expression using short interfering nucleic acid (siNA)
US11/054,047 Continuation-In-Part US20050287128A1 (en) 2001-05-18 2005-02-09 RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
US11/058,582 Continuation-In-Part US20050260620A1 (en) 2001-05-18 2005-02-15 RNA interference mediated inhibition of retinolblastoma (RBI) gene expression using short interfering nucleic acid (siNA)
US11/063,415 Continuation-In-Part US20050277133A1 (en) 2001-05-18 2005-02-22 RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US11/098,303 Continuation-In-Part US20050282188A1 (en) 2001-05-18 2005-04-04 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US11/140,328 Continuation-In-Part US20060019917A1 (en) 2001-05-18 2005-05-27 RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
US11/217,936 Continuation-In-Part US20060148743A1 (en) 2001-05-18 2005-09-01 RNA interference mediated inhibition of histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA)
US11/234,730 Continuation-In-Part US20070270579A1 (en) 2001-05-18 2005-09-23 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US11/265,730 Continuation-In-Part US20070179104A1 (en) 2001-05-18 2005-11-02 RNA interference mediated inhibition of winged helix nude (WHN) gene expression using short interfering nucleic acid (siNA)
US11/299,254 Continuation-In-Part US20060217331A1 (en) 2001-05-18 2005-12-08 Chemically modified double stranded nucleic acid molecules that mediate RNA interference
US11/299,391 Continuation-In-Part US7517864B2 (en) 2001-05-18 2005-12-09 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US11/311,826 Continuation-In-Part US20060211642A1 (en) 2001-05-18 2005-12-19 RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
US11/332,655 Continuation-In-Part US20060276422A1 (en) 2001-05-18 2006-01-13 RNA interference mediated inhibition of B7-H1 gene expression using short interfering nucleic acid (siNA)
US11/395,833 Continuation-In-Part US20060287267A1 (en) 2001-05-18 2006-03-31 RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
US11/448,115 Continuation-In-Part US20060216747A1 (en) 2001-05-18 2006-06-06 RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US11/450,856 Continuation-In-Part US20060270623A1 (en) 2001-05-18 2006-06-09 RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US11/455,205 Continuation-In-Part US20070049543A1 (en) 2001-05-18 2006-06-16 RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
US11/487,788 Continuation-In-Part US20070173473A1 (en) 2001-05-18 2006-07-17 RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
US12/064,014 Continuation-In-Part US20090176725A1 (en) 2005-08-17 2006-08-17 Chemically modified short interfering nucleic acid molecules that mediate rna interference
PCT/US2006/032168 Continuation-In-Part WO2007022369A2 (en) 2001-05-18 2006-08-17 Chemically modified short interfering nucleic acid molecules that mediate rna interference
US11/592,039 Continuation-In-Part US20070185049A1 (en) 2001-05-18 2006-11-02 RNA interference mediated inhibition of histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA)

Publications (2)

Publication Number Publication Date
WO2005041859A2 WO2005041859A2 (en) 2005-05-12
WO2005041859A3 true WO2005041859A3 (en) 2007-04-26

Family

ID=56290557

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/013456 WO2005041859A2 (en) 2000-02-11 2004-04-30 Conjugates and compositions for cellular delivery.

Country Status (2)

Country Link
EP (2) EP3222294A1 (en)
WO (1) WO2005041859A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1784501B1 (en) 2004-05-14 2015-11-18 Rosetta Genomics Ltd VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF
US7795419B2 (en) 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
WO2008036825A2 (en) 2006-09-22 2008-03-27 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by rna interference
EP2171095A4 (en) * 2007-07-06 2012-07-11 Univ Northeastern Mixed micelles including amphipathic conjugates of rna agents, and uses thereof
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
EP2555777B1 (en) 2010-04-09 2019-02-20 Sirna Therapeutics, Inc. Novel single chemical entities and methods for delivery of oligonucleotides
WO2012027206A1 (en) 2010-08-24 2012-03-01 Merck Sharp & Dohme Corp. SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
ES2908978T3 (en) 2010-08-31 2022-05-04 Sirna Therapeutics Inc New simple chemical entities and methods for oligonucleotide delivery
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
TW201808342A (en) 2012-05-02 2018-03-16 喜納製藥公司 Novel tetraGALNAC containing conjugates and methods for delivery of oligonucleotides
AR090905A1 (en) 2012-05-02 2014-12-17 Merck Sharp & Dohme CONJUGATES CONTAINING TETRAGALNAC AND PEPTIDES AND PROCEDURES FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES, PHARMACEUTICAL COMPOSITION
WO2015069586A2 (en) 2013-11-06 2015-05-14 Merck Sharp & Dohme Corp. Dual molecular delivery of oligonucleotides and peptide containing conjugates
WO2015069587A2 (en) 2013-11-06 2015-05-14 Merck Sharp & Dohme Corp. Peptide containing conjugates for dual molecular delivery of oligonucleotides
US10195286B2 (en) 2017-07-04 2019-02-05 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
WO2023081893A1 (en) * 2021-11-08 2023-05-11 Entrada Therapeutics, Inc. Intracellular targeting of oligonucleotides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012096A1 (en) * 1989-04-03 1990-10-18 Purdue Research Foundation Method for enhancing transmembrane transport of exogenous molecules
WO2000044914A1 (en) * 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6168778B1 (en) * 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643889A (en) * 1984-07-11 1997-07-01 Temple University-Of The Commonwealth System Of Pennsylvania Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
KR970005898B1 (en) 1987-09-21 1997-04-21 젠- 프로우브 인코퍼레이티드 Non-nucleotide linking reagents for nucleotide rpobes
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
CA2039718C (en) 1989-08-31 2003-02-25 John J. Rossi Chimeric dna-rna catalytic sequences
AU7759291A (en) 1990-03-29 1991-10-21 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
PL169576B1 (en) 1990-10-12 1996-08-30 Max Planck Gesellschaft Method of obtaining rna molecule of catalytic activity
DE4216134A1 (en) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog SYNTHETIC CATALYTIC OLIGONUCLEOTIDE STRUCTURES
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
WO1993023569A1 (en) 1992-05-11 1993-11-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
US5804683A (en) 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
JPH08507203A (en) 1992-12-04 1996-08-06 イノーバー ラボラトリーズ，インコーポレイテッド Regulatable nucleic acid therapies and methods of their use
EP0681613B1 (en) 1992-12-04 2002-05-08 Yale University Ribozyme amplified diagnostics
US5871914A (en) 1993-06-03 1999-02-16 Intelligene Ltd. Method for detecting a nucleic acid involving the production of a triggering RNA and transcription amplification
EP1253199A1 (en) 1993-09-02 2002-10-30 Ribozyme Pharmaceuticals, Inc. Abasic moieties containing enzymatic nucleic acids
US5861288A (en) 1993-10-18 1999-01-19 Ribozyme Pharmaceuticals, Inc. Catalytic DNA
EP0725788B1 (en) 1993-10-27 1998-12-16 Ribozyme Pharmaceuticals, Inc. 2'-amido and 2'-peptido modified oligonucleotides
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5633133A (en) 1994-07-14 1997-05-27 Long; David M. Ligation with hammerhead ribozymes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5716824A (en) 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
US5872241A (en) 1995-01-25 1999-02-16 The Trustees Of Columbia University In The City Of New York Multiple component RNA catalysts and uses thereof
AU728176B2 (en) 1995-05-04 2001-01-04 Gilead Sciences, Inc. Nucleic acid ligand complexes
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
AU1430097A (en) 1996-01-16 1997-08-11 Ribozyme Pharmaceuticals, Inc. Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US5989912A (en) 1996-11-21 1999-11-23 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
JP2002514913A (en) 1996-12-19 2002-05-21 エール ユニバーシティ Bioreactive allosteric polynucleotide
JP3903392B2 (en) 1996-12-24 2007-04-11 サーナ・セラピューティクス・インコーポレイテッド Chemical synthesis of nucleoside analogues and their introduction into polynucleotides.
US6001311A (en) 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
WO1998043993A2 (en) 1997-03-31 1998-10-08 Yale University Nucleic acid catalysts
AU7976198A (en) 1997-06-19 1999-01-04 Ribozyme Pharmaceuticals, Inc. Hammerhead ribozymes with extended cleavage rule
AR013269A1 (en) 1997-08-04 2000-12-13 Scras PRODUCT CONTAINING AT LEAST A DOUBLE FILAMENT RNA COMBINED WITH AT LEAST AN ANTI-VIRAL AGENT, FOR THERAPEUTIC USE IN THE TREATMENT OF A VIRAL DISEASE, ESPECIALLY OF VIRAL HEPATITIS
AU750947C (en) 1997-09-22 2003-05-22 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Nucleic acid catalysts with endonuclease activity
WO1999017120A1 (en) 1997-09-26 1999-04-08 Becton, Dickinson And Company Preparing conjugates using polyethylene glycol linkers
US6054576A (en) 1997-10-02 2000-04-25 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA
WO1999029842A1 (en) 1997-12-05 1999-06-17 Duke University Nucleic acid mediated rna tagging and rna revision
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
AU3751299A (en) 1998-04-20 1999-11-08 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
JP2002512794A (en) 1998-04-29 2002-05-08 リボザイム・ファーマシューティカルズ・インコーポレーテッド Nucleotide triphosphates and their incorporation into ribozymes
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
IL126731A0 (en) 1998-10-23 1999-08-17 Intelligene Ltd A method of detection
AU772881B2 (en) 1998-11-03 2004-05-13 Yale University Multidomain polynucleotide molecular sensors
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
EP3231445A1 (en) 2001-05-18 2017-10-18 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
KR20040008526A (en) 2002-07-18 2004-01-31 주식회사 하이닉스반도체 Erase method of flash memory cell
US8240498B2 (en) 2006-10-31 2012-08-14 Crown Packaging Technology, Inc. Resealable closure
US9301511B1 (en) 2015-05-05 2016-04-05 Harold Edward Clarambeau Fishing rig with floatation device

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012096A1 (en) * 1989-04-03 1990-10-18 Purdue Research Foundation Method for enhancing transmembrane transport of exogenous molecules
US6168778B1 (en) * 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
WO2000044914A1 (en) * 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CONNOLLY D.T. ET AL.: "Binding and Endocytosis of Cluster Glycosides by Rabbit Hepatocytes", vol. 257, no. 2, January 1982 (1982-01-01), pages 939 - 945, XP003010765 *
RENSEN P.C.N. ET AL.: "Determination of the Upper Size Limit for Uptake and Processing of Ligands by the Asialoglycoprotein Receptor on Hepatocytes in Vitro ad in Vivo", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 40, October 2001 (2001-10-01), pages 37577 - 37584, XP003010766 *

Also Published As

Publication number Publication date
EP1622572A2 (en) 2006-02-08
EP3222294A1 (en) 2017-09-27
WO2005041859A2 (en) 2005-05-12
EP1622572B1 (en) 2017-12-20
EP1622572A4 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
WO2002094185A3 (en) Conjugates and compositions for cellular delivery
WO2005041859A3 (en) Conjugates and compositions for cellular delivery.
WO2003008628A3 (en) Enzymatic nucleic acid peptide conjugates
EP3710586B1 (en) Nucleic acids for inhibiting expression of lpa in a cell
US10612027B2 (en) Modified double-stranded RNA agents
EP2636739B1 (en) iRNA agents targeting VEGF
US8501706B2 (en) Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
WO2007086883A3 (en) Cationic lipids and formulated molecular compositions containing them
WO2006081546A3 (en) Inhibitor nucleic acids
WO2005007196A3 (en) Lipid encapsulated interfering rna
JP2016028605A (en) Lipid-modified double-stranded rna with high rna interference effect
JP2005505504A5 (en)
WO2004007748A3 (en) Deprotection and purification of oligonucleotides and their derivatives
US20130236968A1 (en) Multifunctional copolymers for nucleic acid delivery
EP3034083A3 (en) Antisense oligonucleotides for use in treating myotonic dystrophy
WO2004048545A3 (en) DELIVERY OF siRNAs______________________________________________
EP2264167A1 (en) Double-stranded lipid-modified rna having high rna interference effect
EP2251039A3 (en) Oligo double-stranded rna inhibiting the expression of bcl-2 and pharmaceutical composition containing the same
JP5252622B2 (en) Double-stranded RNA capable of expressing high nuclease resistance and excellent RNA interference effect
Rapozzi et al. Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells
WO2007075655A3 (en) Compositions and methods for altering rnai
EP4281085A1 (en) Modified double stranded oligonucleotides
JP2008167739A (en) Modified type double stranded rna having high rna interference activity
WO2009148955A3 (en) Multi-arm amines and uses thereof
Belousoff et al. Binding of HIV-1 TAR mRNA to a peptide nucleic acid oligomer and its conjugates with metal-ion-binding multidentate ligands

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 10881580

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 10921554

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 10923536

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 11140328

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11217936

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 11234730

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 11265730

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004775924

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11299254

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 11299391

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 11311826

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 11332655

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11140328

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2004775924

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11395833

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 11448115

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 11450856

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 11455205

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10921554

Country of ref document: US

Ref document number: 10881580

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11217936

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 11487788

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11311826

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11448115

Country of ref document: US

Ref document number: 11299391

Country of ref document: US

Ref document number: 11299254

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 11592039

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11450856

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11332655

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11395833

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10923536

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11455205

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11487788

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11265730

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11592039

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11234730

Country of ref document: US